Can my insurer make me fail other drugs before covering a CGRP medication?

Often, yes. Many plans apply step therapy to the CGRP class, requiring a documented trial and failure of one or more older oral preventives first. Whether that holds depends on your specific plan language and your state's step-therapy rules, so read the criteria the denial cites and check whether an exception pathway exists No step therapy is required at the national formulary level for CGRPs; most state step-therapy laws apply only to fully insured plans. ([source](https://www.artificerhealth.com/blog/cgrp-prior-authorization-guide/)).

Headache-society guidance says CGRP can be first-line. Why does my plan still require step therapy?

Because clinical guidance and coverage policy update on different timelines. A headache-society position statement can move CGRP to first-line while a step-therapy protocol written earlier still gates the class behind older drugs The AHS 2023 position statement states CGRP-targeting therapies should be considered a first-line approach for migraine prevention. ([source](https://americanheadachesociety.org/research/library/cgrp-targeting-therapies-as-a-first-line-option-for-migraine-prevention)). The guidance supports your case in an appeal; it doesn't automatically rewrite the insurer's criteria.

What documentation actually helps a CGRP step-therapy appeal?

Specifics with dates. Which older preventives you tried, when, for how long, and exactly why each stopped, including tolerability reactions, not just "it didn't work." A continuous symptom timeline that shows the CGRP drug is reducing attack days strengthens a continuation request. Vague recollection is the weakest possible evidence; dated records are the strongest.

When guidelines say CGRP first-line and your insurer still says fail two drugs first

Article · 3 min read

Your neurologist says CGRP. Your insurer says: fail two drugs first.

Q: Should I stop my CGRP medication while my appeal is pending?

Not as a paperwork move. Letting a working prescription lapse, or restarting an old drug to "re-prove" it fails, can cost you months of stability. Any change during an appeal should be decided with your prescriber. Document the past failure with dates instead of re-living it.

Clinical guidelines moved CGRP preventives to first-line. Most step-therapy policies didn't. The gap runs straight through your paperwork, and this week it moved again.

What changed this week

Another CGRP coverage change has landed. An insurer or state agency altered step-therapy requirements, prior authorization criteria, or formulary placement for the CGRP class. Strip the press-release language and the patient-facing version is short: someone now has to fail an older preventive first, or someone just gained faster access.

If you take erenumab, fremanezumab, galcanezumab, eptinezumab, or a gepant like rimegepant or atogepant, this is the kind of change that doesn't hit you today. It surfaces as a denial letter three refills from now, at plan renewal, when nobody warned you the criteria shifted underneath your prescription.

The class, in case the letter uses initials

"CGRP preventives" covers the monthly/quarterly antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and the oral gepants used for prevention (rimegepant, atogepant). A denial usually names the drug, not the class, so the letter can look narrower than the policy actually is.

The paperwork lag

Here's the pattern under every one of these stories. Clinical consensus and coverage policy run on different clocks, and the distance between them is where patients live.

The American Headache Society updated its position to support CGRP-targeting therapies as a first-line option, not something you earn only after older drugs fail The American Headache Society's 2023 position statement states CGRP-targeting therapies are a first-line option for migraine prevention. ([source](https://americanheadachesociety.org/research/library/cgrp-targeting-therapies-as-a-first-line-option-for-migraine-prevention)). But a step-therapy protocol written before that update doesn't rewrite itself. So the guideline says "reasonable to start here" while the pharmacy benefit rulebook still says "prove two other things failed first." Call it the paperwork lag. It isn't malice. It's a policy document that ages slower than the medicine it governs.

Why 'your doctor decides' stopped being the whole story

Most coverage of migraine treatment still frames it as a conversation between you and your prescriber. Pick the drug together, write the script, done.

For preventives, that hasn't been the full picture for a while. Your neurologist writes what they believe you need. The pharmacy benefit manager's coverage criteria decide whether that same script fills at a ten-dollar copay or a six-hundred-dollar retail price. Two decision-makers, one of them invisible until the denial arrives. The practical move most people miss: when a CGRP drug gets blocked, the thing to push against is the criteria document, not another appointment with the doctor who already agreed with you.

What the criteria actually require vs. what the guidelines say

Read enough denial letters and the language rhymes. Every formulary season, r/migraine and r/cgrpMigraine fill with the same three phrases: "not medically necessary," "step therapy required," "trial and failure of two preventive agents." Different plans, near-identical wording, because they're all working off the same style of criteria template.

The mismatch is easiest to see side by side. On the left is roughly where the guidance sits now. On the right is what a step-therapy policy that hasn't caught up still asks for.

Category-level pattern drawn from published headache-society guidance and recurring CGRP-class step-therapy criteria. Specific plan language varies; verify your own policy's exact wording.
What current guidance supports	What lagging step-therapy still requires
CGRP preventives considered as a first-line option	Documented failure of two or more older oral preventives first
Tolerability failure counts as a reason to switch	Often only efficacy failure counts; side effects may not qualify
Continuing a preventive that's clearly working	Periodic re-review at renewal that can restart the whole gate
Choice guided by the patient's history and comorbidities	A fixed sequence applied before individual history is weighed

How it plays out, one refill at a time

Picture someone two years stable on a CGRP antibody. Fewer attack days, tolerable side effects, finally a schedule they can plan around. Renewal hits. A re-review flags the drug and asks them to re-document a failed trial of an older oral preventive, one they may have quit years ago for good reason.

Now the whole thing hinges on records. Did anyone write down that topiramate brought word-finding trouble, or that a beta-blocker flattened them for a month? Was the tolerability problem dated, or is it a vague memory? The exception request lives or dies on specifics: which drug, what reaction, when, how long. A headache-count app that logs a red dot on attack days has none of that. The days that prove your case are the messy in-between ones, the postdrome fog and the medication reactions, exactly the data most trackers throw away.

Don't stop a working drug to win an argument

Some patients let a CGRP prescription lapse while an appeal is pending, or restart an old drug to "prove" it fails again. Both can cost you months of stability. Any change during an appeal is a conversation with your prescriber, not a paperwork tactic. Document the past failure with dates instead of re-living it.

The record is the whole appeal

Step-therapy exceptions get won on documentation, not on how strongly your neurologist feels. Dated symptom history, dated tolerability reactions, a continuous timeline that shows the drug is working and the alternatives already didn't. That's the file that makes an insurer's reviewer work harder.

We built Postdrome to keep that record without asking you to do accounting. It logs the full arc, the attack and the 24-to-72-hour postdrome after it, the residual photophobia, the brain fog, the medication reactions, on a continuous timeline you own on-device. When a re-review lands, the evidence is already there in dated form, not something you have to reconstruct from memory the week a denial arrives. One price, no subscription, and the data exports so it's yours when your prescriber's office needs it.

What we're tracking next

State step-therapy reform is the thread to watch. Several legislatures have tightened how long an insurer can make a stable patient re-fail a drug, and how fast an exception must be answered. When one of those rules lands, it changes the math on every scenario above. We'll break the next one down the same way: what the release says, then what it means the next time you're at the pharmacy counter.

Keep the dated timeline your next appeal will need. Get Postdrome.

We can't fix your insurer's appeal process. We can give you the documentation that makes their reviewer work harder: a continuous, dated timeline of attacks, postdrome, and medication reactions that a headache-count app never captures. On-device, exportable, one price with no subscription.

Get Postdrome